Therapeutically, this axis can be targeted, as exemplified by a novel STAT3 inhibitor, XYA-2, which co-suppresses MYC and SLC39A10 to elicit anti-tumor effects (181). This evidence concerns the gene SLC39A10 and neoplasm.